Nanotechnology has provided great opportunities for managing neoplastic conditions at
various levels, from preventive and diagnostic to therapeutic fields. However, when it comes …

At the interface between the innate and adaptive immune system, dendritic cells (DCs) play
key roles in tumour immunity and hold a hitherto unrealized potential for cancer …

Abstract Cytokine therapy, involving interleukin-15 (IL-15), is a promising strategy for cancer
immunotherapy. However, clinical application has been limited due to severe toxicity and …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

Effective cancer immunotherapy is usually blocked by immunosuppressive factors in the
tumour microenvironment, resulting in tumour promotion, metastasis and recurrence. Here …

Cell therapies for the treatment of skin disorders could benefit from simple, safe and efficient
technology for the transdermal delivery of therapeutic cells. Conventional cell delivery by …

Dendritic cells (DCs) are a unique class of immune cells that act as a bridge between innate
and adaptive immunity. The discovery of DCs by Cohen and Steinman in 1973 laid the …

Dendritic cell (DC) vaccine was among the first FDA-approved cancer immunotherapies, but
has been limited by the modest cytotoxic T lymphocyte (CTL) response and therapeutic …

Cancer nanovaccines as one of immunotherapeutic approaches are able to attack tumors by
stimulating tumor-specific immunological responses. However, there still exist multiple …

Dendritic cells (DCs) secrete vast quantities of exosomes termed as dexosomes.
Dexosomes are symmetric nanoscale heat-stable vesicles that consist of a lipid bilayer …